BioSpace

Boehringer, Zealand’s obesity drug doesn’t elevate heart risk in key late-stage test

The Phase 3 results help clarify the safety profile of Zealand and Boehringer Ingelheim’s survodutide, but analysts do not think the drug will find utility beyond patients with liver-related risk factors.

By BioSpace

1 min read
Boehringer, Zealand’s obesity drug doesn’t elevate heart risk in key late-stage test
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights